Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

2753 results

Sort By:

Glutide for Ending Methamphetamine

Study ID: NCT07204249
Start Date: 2026-01-15
End Date: 2030-02-15
Study Type

Interventional

Study Phase

Phase2

No. of Participants

162

Intervention / Treatment

Semaglutide

Placebo

Sponsor

San Francisco Department of Public Health

Source: clinicaltrials.gov

Share:
Add to list

Treatment of Skeletal Class II Malocclusion With Modified Twin-Block Appliance With Clear Plates

Study ID: NCT05950581
Start Date: 2026-03-15
End Date: 2026-09-15
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

32

Intervention / Treatment

Modified Twin-Block Appliance with Clear Plates.

Traditional Twin-Block appliance

Sponsor

Hama University

Source: clinicaltrials.gov

Share:
Add to list

A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)

Study ID: NCT06579755
Start Date: 2026-04-01
End Date: 2027-04-14
Study Type

Interventional

Study Phase

Phase3

No. of Participants

800

Intervention / Treatment

TDV

Placebo

Sponsor

Takeda

Source: clinicaltrials.gov

Share:
Add to list

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Study ID: NCT06904066
Start Date: 2025-11-10
End Date: 2029-04-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

86

Intervention / Treatment

far away

cyclophosphamide

fludarabine phosphate

Individual Patient TCR-Transduced PBL

TruSight Oncology (TSO) 500

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Pilot Study of an Aerobic Exercise Intervention During Immune Checkpoint Inhibitor Therapy in Early-stage Triple Negative Breast Cancer

Study ID: NCT07216495
Start Date: 2026-04-06
End Date: 2030-10-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

33

Intervention / Treatment

Exercise

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Voice Therapy Per the Rehabilitation Treatment Specification System

Study ID: NCT06152627
Start Date: 2026-01-01
End Date: 2027-08-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

600

Intervention / Treatment

Standard of care voice therapy with novice clinician RTSS-Voice documentation

Standard of care voice therapy with expert clinician RTSS-Voice documentation

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

Prevalence of Latent Tuberculosis Infection Among Hemodialysis Patients

Study ID: NCT07210970
Start Date: 2025-12-01
End Date: 2027-12-20
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

200

Intervention / Treatment

Tuberculin Skin Test (TST)

Sponsor

Sohag University

Source: clinicaltrials.gov

Share:
Add to list

Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations

Study ID: NCT07112456
Start Date: 2026-09-01
End Date: 2029-08-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

Nebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare

Placebo nebulization (5 mL normal saline) plus standard asthma care

Sponsor

Oman Medical Speciality Board

Source: clinicaltrials.gov

Share:
Add to list

A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)

Study ID: NCT07135973
Start Date: 2025-11-28
End Date: 2028-03-17
Study Type

Interventional

Study Phase

Phase4

No. of Participants

26

Intervention / Treatment

Not yetosudil

Sponsor

Sanofi

Source: clinicaltrials.gov

Share:
Add to list

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Study ID: NCT07222566
Start Date: 2025-12-05
End Date: 2032-08-26
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1500

Intervention / Treatment

PF-08634404

Pembrolizumab

Chemotherapy Regimen 1

Chemotherapy Regimen 2

Sponsor

Pfizer

Source: clinicaltrials.gov

Share:
Add to list